235 related articles for article (PubMed ID: 28859883)
1. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents.
Murai N; Hiyama H; Kiso T; Sekizawa T; Watabiki T; Oka H; Aoki T
Neuropharmacology; 2017 Nov; 126():97-107. PubMed ID: 28859883
[TBL] [Abstract][Full Text] [Related]
2. Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects.
Zhang D; Decker AM; Woodhouse K; Snyder R; Patel P; Harris DL; Tao YX; Li JX; Zhang Y
Eur J Med Chem; 2022 Dec; 243():114741. PubMed ID: 36126387
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Autotaxin and Lysophosphatidic Acid Receptor 5 Attenuates Neuroinflammation in LPS-Activated BV-2 Microglia and a Mouse Endotoxemia Model.
Joshi L; Plastira I; Bernhart E; Reicher H; Triebl A; Köfeler HC; Sattler W
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445223
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid and its receptor LPA
Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
Uchida H; Nagai J; Ueda H
Mol Pain; 2014 Nov; 10():71. PubMed ID: 25411045
[TBL] [Abstract][Full Text] [Related]
6. Identification of potent lysophosphatidic acid receptor 5 (LPA5) antagonists as potential analgesic agents.
Kawamoto Y; Seo R; Murai N; Hiyama H; Oka H
Bioorg Med Chem; 2018 Jan; 26(1):257-265. PubMed ID: 29208511
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs.
Ogawa K; Takasu K; Shinohara S; Yoneda Y; Kato A
Eur J Pain; 2012 Aug; 16(7):994-1004. PubMed ID: 22337641
[TBL] [Abstract][Full Text] [Related]
8. Transient allodynia pain models in mice for early assessment of analgesic activity.
Gil DW; Cheevers CV; Donello JE
Br J Pharmacol; 2008 Feb; 153(4):769-74. PubMed ID: 17700719
[TBL] [Abstract][Full Text] [Related]
9. ASP8477, a fatty acid amide hydrolase inhibitor, exerts analgesic effects in rat models of neuropathic and dysfunctional pain.
Kiso T; Watabiki T; Sekizawa T
Eur J Pharmacol; 2020 Aug; 881():173194. PubMed ID: 32445705
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
[TBL] [Abstract][Full Text] [Related]
11. A critical time window for the analgesic effect of central histamine in the partial sciatic ligation model of neuropathic pain.
Yu J; Tang YY; Wang RR; Lou GD; Hu TT; Hou WW; Yue JX; Ohtsu H; Shi LY; Zhang SH; Chen Z
J Neuroinflammation; 2016 Jun; 13(1):163. PubMed ID: 27342775
[TBL] [Abstract][Full Text] [Related]
12. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats.
Ahn DK; Lee SY; Han SR; Ju JS; Yang GY; Lee MK; Youn DH; Bae YC
Pain; 2009 Nov; 146(1-2):114-20. PubMed ID: 19665300
[TBL] [Abstract][Full Text] [Related]
13. LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model.
Tsukahara R; Yamamoto S; Yoshikawa K; Gotoh M; Tsukahara T; Neyama H; Ishii S; Akahoshi N; Yanagida K; Sumida H; Araki M; Araki K; Yamamura KI; Murakami-Murofushi K; Ueda H
J Pharmacol Sci; 2018 Feb; 136(2):93-96. PubMed ID: 29409686
[TBL] [Abstract][Full Text] [Related]
14. Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain.
Lin ME; Rivera RR; Chun J
J Biol Chem; 2012 May; 287(21):17608-17617. PubMed ID: 22461625
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal delivery of farnesyl thiosalicylic acid and GW 5074 attenuates hyperalgesia and allodynia in chronic constriction injury-induced neuropathic pain in rats.
Jaggi AS; Singh N
Neurol Sci; 2013 Mar; 34(3):297-304. PubMed ID: 22382741
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice.
Ueda H; Neyama H; Matsushita Y
Cells; 2020 Aug; 9(8):. PubMed ID: 32824296
[TBL] [Abstract][Full Text] [Related]
17. LPA5 receptor plays a role in pain sensitivity, emotional exploration and reversal learning.
Callaerts-Vegh Z; Leo S; Vermaercke B; Meert T; D'Hooge R
Genes Brain Behav; 2012 Nov; 11(8):1009-19. PubMed ID: 23039190
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive effects of AS1069562, the (+)-isomer of indeloxazine, on spinal hypersensitivity induced by intrathecal injection of prostaglandin in mice: comparison with duloxetine and amitriptyline.
Murai N; Tsukamoto M; Tamura S; Aoki T; Matsuoka N
Eur J Pharmacol; 2014 Jun; 733():54-61. PubMed ID: 24704374
[TBL] [Abstract][Full Text] [Related]
19. Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid.
Inoue M; Xie W; Matsushita Y; Chun J; Aoki J; Ueda H
Neuroscience; 2008 Mar; 152(2):296-8. PubMed ID: 18280050
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive effect of intrathecal administration of hypotaurine in rat models of inflammatory and neuropathic pain.
Hara K; Nakamura M; Haranishi Y; Terada T; Kataoka K; Sata T
Amino Acids; 2012 Jul; 43(1):397-404. PubMed ID: 21971909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
